Investors - Mendus

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific advisory board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Convertible bonds
Analyst coverage
Financial reports
Financial calendar
Rights Issue and Directed Issue 2023
Letter from the CEOTransitioning Towards Late-Stage Development
In 2023, Mendus put in place the building blocks that allow us to transition into a late-stage clinical development company. The positive Phase 2 data with our lead product vididencel in acute myeloid leukemia (AML) presented at the ASH conference in December capped a year with strong progress.
To read the full letter from the CEO, please click here.
Rights Issue and Directed Issue 2023You will find all relevant information that are published in connection with the proposed rights issue and directed issue in Mendus on this page.
Update on Vididencel Program – Webcast and On-Site EventMendus provided an update on its lead program vididencel on Tuesday, June 27, 2023. The update took place in an online event and, separately, on-site at the company’s headquarters in Stockholm, Sweden.
The replay of the online event is accessible via the link below.
Vididencel Development Update – Webcast Replay
Latest Company PresentationView the latest company presentation
 
ASH 2022 WebcastWatch the replay
 
Mendus KOL Event – November 2022Watch the replay
 
Latest press releasesApril 2024Regulatory Release
Mendus publishes Annual Report for 2023
Press releaseStockholm, Sweden, April 17, 2024Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that the Annual Report for 2023 has been published. The Annual Report is attached as a PDF and is available on the
Learn more
April 2024Regulatory Release
Notice of Annual General Meeting in Mendus AB (publ)
Learn more
EventsApril 2024
Mendus CEO Erik Manting presented at the Invest in Oncology Forum held in Stockholm on April 10, 2024
Learn more
March 2024
CEO Erik Manting interview at Inderes on March 12, 2024
Learn more

Contact
Telephone+46 (0)8 732 8400
Emailinfo@mendus.com
<picture><source type="image/webp" srcSet="/static/411b7857055b0888002108e1bcc9e280/e64f1/heado.webp 100w,/static/411b7857055b0888002108e1bcc9e280/8b00d/heado.webp 200w,/static/411b7857055b0888002108e1bcc9e280/9c0a1/heado.webp 400w,/static/411b7857055b0888002108e1bcc9e280/88f3e/heado.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg" srcSet="/static/411b7857055b0888002108e1bcc9e280/93e3f/heado.jpg 100w,/static/411b7857055b0888002108e1bcc9e280/839ae/heado.jpg 200w,/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg 400w,/static/411b7857055b0888002108e1bcc9e280/a677a/heado.jpg 800w" alt="&lt;p&gt;Image of old buildings by a dock with boats laying in the water in the foreground.&lt;/p&gt;
"/></picture>
Head OfficeVästra Trädgårdsgatan 15

111 53 Stockholm

Sweden
<picture><source type="image/webp" srcSet="/static/99d97027eda87168e92d8d30678ace5b/e64f1/rdo.webp 100w,/static/99d97027eda87168e92d8d30678ace5b/8b00d/rdo.webp 200w,/static/99d97027eda87168e92d8d30678ace5b/9b01d/rdo.webp 400w,/static/99d97027eda87168e92d8d30678ace5b/08dc5/rdo.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg" srcSet="/static/99d97027eda87168e92d8d30678ace5b/93e3f/rdo.jpg 100w,/static/99d97027eda87168e92d8d30678ace5b/839ae/rdo.jpg 200w,/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg 400w,/static/99d97027eda87168e92d8d30678ace5b/3f065/rdo.jpg 800w" alt="&lt;p&gt;City image from a walkway, with a church and tall buildings in the background.&lt;/p&gt;
"/></picture>
R&D OfficesEmmy Noetherweg 2K 

2333 BK Leiden

The Netherlands
<picture><source type="image/webp" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/e64f1/go.webp 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/8b00d/go.webp 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/9c0a1/go.webp 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/88f3e/go.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/93e3f/go.jpg 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/839ae/go.jpg 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/a677a/go.jpg 800w" alt="&lt;p&gt;Overview image of a city, shot in low sunlight from a far distance.&lt;/p&gt;
"/></picture>
Gothenburg OfficeMendus C/O AstraZeneca BioventureHub

Pepparedsleden 1

431 83 Mölndal

Sweden

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1479869476-wsRLvGgNuUHKvLaYoXfco5:before { opacity: 1; background-image: url('/static/a32348a89302674e113dc101e935b7b3/afb86/about-us-mobile.png'); }

News & eventsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
News & Events